跳至主要内容
临床试验/ACTRN12612001090808
ACTRN12612001090808尚未招募未知

Monitoring the Efficacy of Artesunate+Sulfadoxine-Pyrimethamine and Artemether Plus Lumefantrine in Uncomplicated Falciparum Malaria in Pakistan

Bannu Medical College0 个研究点目标入组 240 人开始时间: 2012年10月12日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
6 Months 至 o limit(—)
性别
All

入选标准

  • 1. Age greater than 6 months, excluding 12-17 old female minors and unmarried females aged 18 years and above;
  • 2. mono-infection with P. falciparum detected by microscopy;
  • 3. Parasitaemia of 1000 – 250000 / microlitre asexual forms for sites in Sindh, Balochistan and Khyber Pakhtoonkwa.
  • 4. Presence of axillary temperature equal to or greater than 37.5 degrees celsius or history of fever during the past 48 h;
  • 5. Ability to swallow oral medication;
  • 6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
  • 7. Informed consent from the patient or from a parent or guardian in the case of children.

排除标准

  • 1. Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
  • 2. Mixed or mono-infection with another Plasmodium species detected by microscopy;
  • 3. Presence of severe malnutrition (defined as a child whose growth standard is below –3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference less than 110 mm);
  • 4. Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
  • 5. Regular medication, which may interfere with antimalarial pharmacokinetics;
  • 6. History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); and
  • 7. 12-17 old female minors and unmarried females aged 18 years and above;

研究者

发起方
Bannu Medical College

相似试验

已完成
不适用
Efficacy and safety of artesunate and sulfadoxine-pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in low to moderate sentinel sites in SudaMalaria
ISRCTN45665690World Health Organization (WHO)/HIV/AIDS, Tuberculosis and Malaria (HTM) - Global Malaria Programme180
已完成
不适用
Efficacy and safety of artesunate and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of vivax malaria in Nangarhar, Takhar and Faryab provinces, AfghanistaInfections and InfestationsMalaria
ISRCTN40223079World Health Organization (WHO) (Switzerland)300
已完成
4 期
Efficacy and safety of artesunate+ sulfadoxine/ pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Jamame (Lower Jubba region), Janaale (Lower Shabelle region) and Jowhar (Middle Shabelle region), SomaliaInfection - Other infectious diseasesMalaria
ACTRN12611001009909Ministry of Health264
已完成
不适用
Efficacy and safety of artesunate+sulfadoxine/ pyrimethamine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bosaso, Puntland, SomaliaMalaria
ACTRN12615000049572Ministry of Health, Puntland, Somalia176
招募中
不适用
Efficacy and safety of Artesunate plus Sulphadoxine-Pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in malaria control center Asadabad in Kunar province of Afghanista
ACTRN12612001049864Research Department, Ministry of Publich Health, Afgahnistan88